Ambrx partners with Zhejiang for breast cancer antibody drug conjugate development

Targeting Her2-positive breast cancer, ARX788 is developed by the clinical stage biopharmaceutical company Ambrx as site-specific ADC.

According to the deal, both the companies will continue developing the ADC while the ongoing development cost will be funded by ZMC and will assume manufacturing activities for clinical and commercial necessities across the globe.

Ambrx chief executive officer Lawson Macartney said, "This collaboration allows Ambrx to further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC."

ZMC gains commercial rights to the drug candidate in China, while rights outside the country will reamin with Ambrx, which is also eligible for sales-based royalties.

All the integrated services such as development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials related to ARX788 will be offered by WuXi PharmaTech.

Zhejiang Medicine chairman Chunbo Li said, "We will work with WuXi PharmaTech to accelerate the development and commercialization of ARX788 in China to bring benefits to Her2-positive cancer patients."